GlassScriptPhysician profile
Jennifer Turkish
NPI 1801937123
$15,497.56
in general payments reported to CMS, 2019-2025
51 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $2,141 · 2021: $1,665 · 2022: $1,578 · 2023: $2,391 · 2024: $3,400 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,011.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,559.28 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $2,402.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,237.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,120.90 | 2019-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,039.53 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $756.37 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Allergan, INC. | $601.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.29 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $564.57 | 2019-2023 | |
| Pfizer INC. | $486.27 | 2019-2025 | |
| Amgen INC. | $370.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $296.69 | 2019-2024 | Austedo Xr, Ajovy |
| Merck Sharp & Dohme LLC | $271.78 | 2019-2022 | |
| Daiichi Sankyo INC. | $225.98 | 2019-2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $219.54 | 2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Turkish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.